Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 5/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 4/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25017196 | 0.95 | F10 (0.47) | F10MCHR1TLR9TLR7F2 | |
| SCHEMBL25017513 | 0.91 | ST14 (0.47) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL25016220 | 0.90 | F10 (0.43) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL25016829 | 0.90 | F10 (0.41) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL25017199 | 0.90 | TLR9 (0.44) | F10MCHR1TLR9TLR7F2 | |
| SCHEMBL25015974 | 0.89 | ST14 (0.43) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL25016941 | 0.89 | F10 (0.42) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL25016476 | 0.88 | F10 (0.42) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL25017123 | 0.88 | F10 (0.49) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL25017106 | 0.88 | F10 (0.49) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | F10 1548/4885MCHR1 3680/4885TLR9 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.